Unregulated Peptide Use Poses Public Health Risks via Digital Promotion and Gray-Market Access

While peptide-based medicines offer significant therapeutic potential when developed and administered through regulated pathways, a growing trend of unregulated peptide use is emerging within online biohacking and wellness communities. This phenomenon presents a distinct public health challenge, as individuals experiment with substances for various goals, including fat loss, recovery, aesthetics, cognition, performance, and longevity, often without professional guidance or quality assurance. The critical gap lies in the proliferation of experimental or weakly evidenced peptides outside established clinical and regulatory frameworks, creating an environment ripe for potential harm.

This narrative review systematically examined the landscape of unregulated peptide use, synthesizing existing literature and observations to identify key contributing factors and associated public health risks. Researchers analyzed how various elements interact to normalize the use of poorly traceable peptide products outside clinical supervision. The review focused on understanding the mechanisms of digital promotion, the dynamics of gray-market access, and consumer behaviors such as self-injection, stacking, and informal titration, contrasting these practices with the regulated development and use of legitimate peptide therapeutics.

The review identified several interacting factors contributing to the emerging public health concern of unregulated peptide use. Digital platforms extensively promote experimental or weakly evidenced peptides, normalizing their use for diverse applications like fat loss, recovery, aesthetics, cognition, performance, and longevity. Gray-market access channels facilitate the widespread availability of these products, often bypassing stringent quality controls. Practices such as self-injection, peptide stacking (combining multiple peptides), and informal titration (self-adjusting doses) are common among users, further elevating health risks. The review highlighted significant issues with product-quality uncertainty, including concerns about identity, purity, potency, and sterility, alongside a pervasive regulatory ambiguity and weak pharmacovigilance. These factors collectively lead to a normalization of poorly traceable peptide products outside clinical oversight. The central concern is not legitimate peptide medicine, but consumer experimentation with products of uncertain identity, purity, potency, sterility, and safety.